Brief: Phio Presents New Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL At SITC 2020
09/11/2020 14:18
Nov 9 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO ANNOUNCES POSITIVE IN VIVO DATA ON COMBINATION PD-1
AND
TIGIT CHECKPOINT BLOCKADE WITH INTASYL IN A SINGLE THERAPEUTIC
FOR CANCER TREATMENT
* PHIO PHARMACEUTICALS - NEW DATA ON COMBINATION PD-1 AND
TIGIT
CHECKPOINT BLOCKADE WITH INTASYL WAS PRESENTED AT SITC 2020
VIRTUAL SCIENTIFIC PROGRAM
Source text for Eikon: ID:nPn2c2WS6a
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing